Riverain Technologies

Riverain Technologies announced that its ClearRead CT, a breakthrough nodule detection application, has received clearance from the U.S. Food and Drug Administration (FDA).

Licenses sold worldwide through October for Riverain Technologies’ ClearRead software are up 36 percent compared to the same time period last year.

New software by Riverain Technologies that improves the visual clarity of conventional chest X-ray images and increases radiologists’ efficiency by reducing the time it takes to accurately confirm the proper placement of lifesaving feeding, drug-delivery and pain management tubes and lines has received CE Mark approval.

Riverain Technologies, an industry leader and innovator in proprietary image processing and machine learning technologies, announced that the United States Patent and Trademark Office (USPTO) has awarded the company broad patents for its technologies, opening the door for the company’s software to be used in wider healthcare applications and in other industries. These two new patents not only protect Riverain’s novel chest X-ray technology, which suppresses bone and calls out suspicious tissue, but also hold enormous promise for the company to bring its breakthrough software to other medical applications, including; computed tomography (CT) scans, magnetic resonance imaging (MRI) and ultrasound.

September 14, 2012 — A radiologist’s ability to detect pneumonia early — so it can be treated quickly — is improved by Riverain Technologies software that suppresses the ribs and clavicles on a chest X-ray, suggests new research published online by European Radiology.